
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc. demonstrated a robust financial performance, with a 21% year-over-year growth in top-line revenue for Q3, fueled by a 13% increase in volume and a 5% rise in average selling prices. The company also achieved its highest cash collections in history in October and recorded a notable 19% growth in kidney surveillance volumes in the previous quarter, showcasing strong demand for its testing services. Furthermore, a substantial expansion of its sales force by approximately 50% is expected to enhance future revenue growth, positioning CareDx favorably in the precision medicine market for transplant patients.
Bears say
CareDx Inc. experienced a year-over-year growth in testing volumes of 13%, but the Q3'25 results fell short of expectations, with actual volumes at 50,000 compared to the anticipated 51,000, signaling potential challenges in volume growth despite a 20% increase in surveillance testing. The company's stock performances have faced pressure, trading significantly below historical averages at 1.4x projected 2026 revenue estimates, indicating investor concerns about the future profitability and competitiveness within the diagnostics space. Additionally, CareDx's ongoing risks include management instability over the past three years and uncertainty regarding the commercialization of new diagnostic solutions, which are critical for its growth strategy.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares